BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase I Study in Patients with Advanced Parkinson’s Disease

BlueRock Therapeutics announced the dose administration for the first patient in a Phase I, open-label study of PSC-derived dopaminergic neurons in patients with advanced Parkinson’s disease.